Werthwein S, Bauer U, Nakazi M, Kathmann M, Schlicker E
Institut für Pharmakologie und Toxikologie, Universität Bonn, Germany.
Br J Pharmacol. 1999 May;127(1):300-8. doi: 10.1038/sj.bjp.0702534.
Mouse brain slices preincubated with [3H]-noradrenaline or [3H]-serotonin were superfused with medium containing naloxone 10 microM; we studied whether nociceptin (the endogenous ligand at ORL1 receptors) affects monoamine release. Furthermore, the affinities of ORL1 ligands were determined using [3H]-nociceptin binding. The electrically (0.3 Hz) evoked tritium overflow in mouse cortex slices preincubated with [3H]-noradrenaline was inhibited by nociceptin and [Tyr14]-nociceptin (maximally by 80%; pEC50 7.52 and 8.28) but not affected by [des-Phe1]-nociceptin (pEC50<6). The ORL1 antagonist naloxone benzoylhydrazone antagonized the effect of nociceptin and [Tyr14]-nociceptin. The effect of nociceptin did not desensitize, was not affected by blockade of NO synthase, cyclooxygenase and P1-purinoceptors and was decreased by the alpha2-adrenoceptor agonist talipexole. Nociceptin also inhibited the evoked overflow in mouse cerebellar, hippocampal and hypothalamic slices in a manner sensitive to naloxone benzoylhydrazone. The electrically (3 Hz) evoked tritium overflow in mouse cortex slices preincubated with [3H]-serotonin was inhibited by nociceptin; naloxone benzoylhydrazone antagonized this effect. The affinities (pKi) for [3H]-nociceptin binding to mouse cortex membranes were: nociceptin, 8.71; [Tyr14]-nociceptin, 9.82; [des-Phe1]-nociceptin, <5.5; naloxone benzoylhydrazone, 5.85; naloxone, <4.5. In conclusion, nociceptin inhibits noradrenaline release in the mouse cortex via ORL1 receptors, which interact with presynaptic alpha2-autoreceptors on noradrenergic neurones. The effect of nociceptin does not desensitize nor does it involve NO, prostanoids or adenosine. Nociceptin also attenuates noradrenaline release from several subcortical regions and serotonin release from cortical slices by a naloxone benzoylhydrazone-sensitive mechanism.
用[3H]-去甲肾上腺素或[3H]-5-羟色胺预孵育的小鼠脑片,用含10微摩尔纳洛酮的培养基进行灌流;我们研究了孤啡肽(ORL1受体的内源性配体)是否影响单胺释放。此外,使用[3H]-孤啡肽结合法测定了ORL1配体的亲和力。在预先用[3H]-去甲肾上腺素预孵育的小鼠皮层切片中,电刺激(0.3赫兹)诱发的氚外流受到孤啡肽和[酪氨酸14]-孤啡肽的抑制(最大抑制率达80%;pEC50分别为7.52和8.28),但不受[去苯丙氨酸1]-孤啡肽的影响(pEC50<6)。ORL1拮抗剂纳洛酮苯甲酰腙可拮抗孤啡肽和[酪氨酸14]-孤啡肽的作用。孤啡肽的作用不会脱敏,不受一氧化氮合酶、环氧化酶和P1嘌呤受体阻断的影响,而α2肾上腺素能受体激动剂他利克索可使其作用减弱。孤啡肽还以对纳洛酮苯甲酰腙敏感的方式抑制小鼠小脑、海马和下丘脑切片中诱发的外流。在预先用[3H]-5-羟色胺预孵育的小鼠皮层切片中,电刺激(3赫兹)诱发的氚外流受到孤啡肽的抑制;纳洛酮苯甲酰腙可拮抗此作用。[3H]-孤啡肽与小鼠皮层膜结合的亲和力(pKi)分别为:孤啡肽,8.71;[酪氨酸14]-孤啡肽,9.82;[去苯丙氨酸1]-孤啡肽,<5.5;纳洛酮苯甲酰腙,5.85;纳洛酮,<4.5。总之,孤啡肽通过ORL1受体抑制小鼠皮层中的去甲肾上腺素释放,该受体与去甲肾上腺素能神经元上的突触前α2自受体相互作用。孤啡肽的作用不会脱敏,也不涉及一氧化氮、前列腺素或腺苷。孤啡肽还通过一种对纳洛酮苯甲酰腙敏感的机制减弱来自几个皮层下区域的去甲肾上腺素释放以及皮层切片中的5-羟色胺释放。